BamSEC and AlphaSense Join Forces
Learn More

Dianthus Therapeutics Inc. – Material Contracts

NASDAQ: DNTH    
Share price (6/2/26): $81.57    
Market cap (6/2/26): $4.459 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.22
from 10-K 90 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) the Type That the Registrant Normally Treats as Private and Confidential. Such Excluded Information Has Been Marked “[***]”. License and Collaboration Agreement by and Between Nanjing Leads Biolabs Co. Ltd. and Dianthus Therapeutics, Inc. Dated as of October 16, 2025
12/34/56
EX-10.21
from 10-K 12 pages Dianthus Therapeutics, Inc. Equity Inducement Plan Amended and Restated on December 17, 2025
12/34/56
EX-10.1
from 10-Q 9 pages Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan 1
12/34/56
EX-10.1
from 8-K 13 pages Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan
12/34/56
EX-10.22
from 10-K 9 pages Material contract
12/34/56
EX-10.20
from 10-K 9 pages Material contract
12/34/56
EX-10.19
from 10-K 9 pages The Purpose of This Letter Agreement (“Agreement”) Is to Confirm the Terms of Your Separation of Employment From Magenta Therapeutics, Inc. (“Magenta” or the “Company”).1 the Consideration Being Offered Below Is Contingent on Your Agreement to and Compliance With the Provisions of This Agreement. This Agreement Shall Be Effective on the Eighth (8th) Day After You Sign It (The “Effective Date”), at Which Time It Shall Become Final and Binding on All Parties. 1. Separation Date/ Final Wages/ Benefits Cessation. A
12/34/56
EX-10.15
from 10-K 6 pages Re: Amendment to Offer Letter Dear Sim: By Way of This Letter, Section 5 of Your Offer Letter Dated January 17, 2022 (The “Offer Letter”) by and Between You and Dianthus Therapeutics Opco, Inc. (F/K/a Dianthus Therapeutics, Inc.) (The “Company”) Is Hereby Amended to and Restated in Its Entirety to Read as Follows: “5. Severance Benefits
12/34/56
EX-10.8
from 10-K 8 pages Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan Stock Option Agreement
12/34/56
EX-10.6
from 10-K 11 pages Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan
12/34/56
EX-10.2
from 8-K 44 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 63 pages Securities Purchase Agreement
12/34/56
EX-10.12
from 10-Q 9 pages Material contract
12/34/56
EX-10.7
from 8-K 5 pages Edward Carr Re: Termination of Severance Letter and Amendment to Offer Letter Dear Ed
12/34/56
EX-10.6
from 8-K 5 pages Re: Amendment to Offer Letter Dear Ryan: By Way of This Letter, Section 5 of Your Offer Letter Dated January 18, 2022 (The “Offer Letter”) by and Between You and Dianthus Therapeutics Opco, Inc. (F/K/a Dianthus Therapeutics, Inc.) (The “Company”) Is Hereby Amended to and Restated in Its Entirety to Read as Follows: “5. Severance Benefits
12/34/56
EX-10.5
from 8-K 5 pages Re: Amendment to Offer Letter Dear Marino: By Way of This Letter, Section 5 of Your Offer Letter Dated October 31, 2021 (The “Offer Letter”) by and Between You and Dianthus Therapeutics Opco, Inc. (F/K/a Dianthus Therapeutics, Inc.) (The “Company”) Is Hereby Amended to and Restated in Its Entirety to Read as Follows: “5. Severance Benefits
12/34/56
EX-10.4
from 8-K 12 pages Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan
12/34/56
EX-10.3
from 8-K 10 pages Dianthus Therapeutics, Inc. Form of Officer Indemnification Agreement
12/34/56
EX-10.2
from 8-K 10 pages Dianthus Therapeutics, Inc. Form of Director Indemnification Agreement
12/34/56
EX-10.1
from 8-K 19 pages Contingent Value Rights Agreement
12/34/56